Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuEST1: Immunotherapy Combination in CRPC
NCT03493945Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2018
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bintrafusp alfa, nogapendekin alfa inbakicept, MVA-BN-Brachyury, FPV-Brachyury and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) and solid tumor (advanced stage) (7 arms), sponsored by National Cancer Institute. Primary endpoints: Clinical Benefit (Objective Response or PSA Decline) at 49 weeks and Dose-limiting Toxicities at 21 days. Started May 2018; status: completed.
02
Drugs
bintrafusp alfanogapendekin alfa inbakiceptMVA-BN-BrachyuryFPV-Brachyuryepacadostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03493945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03493945.